Long noncoding RNA SNHG16 promotes the tumorigenicity of cervical cancer cells by recruiting transcriptional factor SPI1 to upregulate PARP9
Authors:
- 27 November 2019
- journal article
- research article
- Published by Wiley in Cell Biology International
- Vol. 44 (3) , 773-784
Abstract
Long noncoding RNA (lncRNA) small nucleolar RNA host gene 16 (SNHG16) has been linked to multiple cancers including breast, ovarian, bladder and colorectal cancer. However, the role of SNHG16 in cervical cancer is unclear. Here, quantitative analysis of SNHG16 and PARP9 expression levels in cervical cancer tissues and cell lines indicated that both SNHG16 and PARP9 were highly expressed compared to controls. Using the dual luciferase reporter gene assay, RNA immunoprecipitation, chromatin immunoprecipitation, we were able to determine that SNHG16 recruited SPI1 protein to promote transcription of PARP9 to upregulate its transcription in cervical cancer cells. After ectopic expression and knockdown experiments were conducted, it was observed that silencing SNHG16 inhibited PARP9 expression, proliferation and invasion of cervical cancer cells, which was rescued by co‐transfection of SNHG16 silencing and PARP9 overexpression. Moreover, in vivo experimental results showed that silencing SNHG16 reduced the expression of PARP9 and suppressed tumor growth. These data indicate that SNHG16 recruits SPI1 to upregulate PARP9, which promotes the tumorigenicity of cervical cancer cells. The regulation of their expression might provide a new direction for treating cervical cancer.Keywords
This publication has 21 references indexed in Scilit:
- Integrated genomic and molecular characterization of cervical cancerNature, 2017
- Transcriptional regulation of the proto‐oncogene Zfp521 by SPI1 (PU.1) and HOXC13Genesis, 2016
- SNHG16 is regulated by the Wnt pathway in colorectal cancer and affects genes involved in lipid metabolismMolecular Oncology, 2016
- A somatic mutation of GFI1B identified in leukemia alters cell fate via a SPI1 (PU.1) centered genetic regulatory networkDevelopmental Biology, 2016
- Poly(ADP-ribose) polymerase inhibitor therapeutic effect: are we just scratching the surface?Expert Opinion on Therapeutic Targets, 2015
- Inference of transcriptional regulation in cancersProceedings of the National Academy of Sciences, 2015
- New PARP targets for cancer therapyNature Reviews Cancer, 2014
- A systematic analysis of the PARP protein family identifies new functions critical for cell physiologyNature Communications, 2013
- ETS transcription factors and their emerging roles in human cancerEuropean Journal of Cancer, 2005
- Regulation of the human poly(ADP-ribose) polymerase promoter by the ETS transcription factorOncogene, 1999